Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm®) in psoriasis

Abstract Objective The aim of this study was to assess the clinical efficacy of long-term (>6 months) oral fumarate maintenance treatment regimen and to determine its adverse effect profile. Background We previously showed the efficacy of oral fumarate treatment in psoriasis. However, little is known about long-term maintenance therapy with oral fumarates. Because of concern about renal toxicity and/or other potentially hazardous adverse effects, their role in the long-term management of psoriasis is still controversial and limited. Methods Clinical data and laboratory parameters of 83 psoriasis patients who were treated with oral fumarates during an uninterrupted period of 6 or more months, were collected and subsequently analysed. Results In 31 of the 83 patients the oral fumarate therapy was discontinued preliminarily ( Conclusion Oral fumarates are effective well tolerated drugs suitable for long-term management of psoriasis. However, this systemic therapy still has to be considered experimental and should only be performed under strictly controlled conditions. The cause and the clinical relevance of the relative lymphocytopenia, which occurs in a high percentage of patients during long-term oral fumarate maintenance treatment regimen are unknown and still have to be determined.